News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
7,407 Results
Type
Article (123)
Press Release (7284)
Section
Business (4907)
Deals (570)
Drug Development (424)
FDA (50)
Job Trends (203)
News (5524)
Policy (167)
Tag
Academia (9)
Accelerated approval (3)
Allergies (1)
Alliances (132)
Alzheimer's disease (5)
Antibody-drug conjugate (ADC) (3)
Approvals (49)
Artificial intelligence (1)
Bankruptcy (1)
Best Places to Work (194)
Breast cancer (5)
Cancer (39)
Cardiovascular disease (4)
CAR-T (1)
Cell therapy (8)
Clinical research (401)
Collaboration (5)
Compensation (4)
Complete response letters (1)
COVID-19 (11)
C-suite (2)
Data (45)
Diagnostics (115)
Drug discovery (2)
Earnings (5238)
Events (320)
Executive appointments (1)
FDA (131)
Fibrodysplasia Ossificans Progressiva (1)
Funding (1)
Gene therapy (6)
GLP-1 (7)
Government (20)
Guidances (65)
Healthcare (225)
Immunology and inflammation (2)
Indications (2)
Infectious disease (12)
Inflammatory bowel disease (1)
Intellectual property (1)
IPO (499)
Job creations (16)
Layoffs (2)
Legal (25)
Lung cancer (5)
Lymphoma (6)
Manufacturing (3)
Medical device (225)
Medtech (225)
Mergers & acquisitions (76)
Metabolic disorders (1)
Multiple sclerosis (3)
Neurodegenerative disease (1)
Neuropsychiatric disorders (1)
Neuroscience (13)
NextGen: Class of 2026 (67)
Non-profit (10)
Obesity (1)
Ovarian cancer (1)
Pain (2)
Patents (2)
Patient recruitment (1)
People (98)
Pharmacy benefit managers (1)
Phase 1 (90)
Phase 2 (143)
Phase 3 (185)
Pipeline (225)
Postmarket research (17)
Preclinical (37)
Prostate cancer (1)
Radiopharmaceuticals (3)
Rare diseases (2)
Real estate (9)
Regulatory (144)
Reports (1)
Research institute (9)
Rett syndrome (1)
RSV (1)
Schizophrenia (2)
Startups (5)
Vaccines (5)
Date
Today (3)
Last 7 days (11)
Last 30 days (26)
Last 365 days (560)
2026 (32)
2025 (563)
2024 (606)
2023 (672)
2022 (768)
2021 (828)
2020 (706)
2019 (482)
2018 (399)
2017 (276)
2016 (158)
2015 (189)
2014 (126)
2013 (80)
2012 (135)
2011 (167)
2010 (189)
Location
Africa (4)
Alabama (1)
Arizona (2)
Asia (279)
Australia (18)
California (175)
Canada (48)
China (9)
Colorado (8)
Connecticut (8)
Delaware (4)
Europe (821)
Florida (33)
Georgia (10)
Idaho (1)
Illinois (11)
India (1)
Indiana (16)
Japan (1)
Kentucky (1)
Louisiana (3)
Maine (4)
Maryland (23)
Massachusetts (115)
Michigan (8)
Minnesota (12)
New Hampshire (1)
New Jersey (57)
New York (122)
North Carolina (20)
Northern California (92)
Ohio (2)
Pennsylvania (36)
South America (15)
Southern California (70)
Texas (26)
United States (712)
Utah (6)
Washington State (14)
Wisconsin (4)
7,407 Results for "486".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Tangential Flow Filtration Market to Hit $4.86 Billion by 2032, at a CAGR of 12.5%, says Coherent Market Insights
September 15, 2025
·
1 min read
Press Releases
Nausea Medicine Market Poised to Hit USD 4.86 Billion by 2032 as Cancer Treatments Intensify | Coherent Market Insights
July 29, 2025
·
1 min read
Press Releases
DiGeorge Syndrome Market Expected to Exhibit a CAGR Of 4.86% During 2025-2035, impelled by Advancements in Early Detection and Genetic Testing
January 29, 2025
·
10 min read
Business
Chiesi Inks Potential $486M Deal with Gossamer Bio for Blood Pressure Treatment
The Italian pharma will gain access to Gossamer Bio’s candidate seralutinib, which reached its primary endpoint in a Phase II pulmonary arterial hypertension trial in 2022 and started a Phase III study last year.
May 6, 2024
·
2 min read
·
Tyler Patchen
Biotech Beach
Erasca Announces Pricing of Underwritten Offering of Common Stock - May 17, 2024
Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share.
May 16, 2024
·
4 min read
Pharm Country
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
BioXcel Therapeutics, Inc. today reported that the European Patent Office (EPO) granted the Company’s European Patent No. 3,562,486 (the “486 patent”) on March 13, 2024.
March 15, 2024
·
10 min read
Urology Imaging Systems Market Is Anticipated to Grow Significantly to Reach US$ 486.4 Million By 2028 - Comprehensive Research Report By FMI
DUBAI, United Arab Emirates, According to the latest research by the FMI, the global urology imaging systems market is expected to account for over US$ 486.4 Mn, in terms of value, by 2028 end.
April 29, 2022
·
5 min read
Business
Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results
Jacobio Pharmaceuticals announces its first annual results after its IPO. Revenue was CNY486 million; R&D costs exceeded CNY230 million, increasing 66% year-on-year.
March 29, 2021
·
2 min read
Pharm Country
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg ® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
April 23, 2021
·
13 min read
Res Nova Biologics Announces First Cancer Patient Treated with FloraStilbene™
Therapeutic Solutions International, Inc. (TSOI), announced today the successful first treatment of a patient with FloraStilbene™, a patent pending formulation of the abortion pill’s active ingredient, RU486, and pterostilbene.
October 20, 2023
·
3 min read
1 of 741
Next
